A French retrospective study describing the epidemiology and the therapeutic management of patients treated by Herceptin® based neoadjuvant treatment for HER2-positive early breast cancer. FRESH-PEF74138-en Camille BACHOT A French retrospective study describing the epidemiology and the therapeutic management of patients treated by Herceptin® based neoadjuvant treatment for HER2-positive early breast cancer. KADOR FRESH-PEF74138-en 74138 FRESH-PEF74138 F. HOFFMANN-LA ROCHE AG Epidemiology France Portal (PEF) null ;Medical data center Herceptin Oncology Carcinoma in situ of breast Healthcare system determinants: Use of care Healthcare system determinants Primary objective: To describe therapeutic management of HER2-positive early breast cancer adults’ patients who have received an adjuvant treatment following Herceptin® based neoadjuvant therapy and breast surgery. Secondary objectives: The 2 key secondary objectives are: 1. To describe the clinical characteristics of the patients included in the cohort, overall and per pathological response status; 2. To measure the invasive disease-free survival (IDFS) and overall survival (OS), according to pathologic response status. Other objectives: 3. To characterize adjuvant treatment failure outcomes including death, disease progression, and relapses; 4. To describe health care resources utilization by the targeted patients; 5. To estimate the number of HER2-positive early breast cancer patients who underwent breast surgery following Herceptin® based neoadjuvant treatment in France over a year (through the constitution of a registry of these patients) and number of HER2 positive early breast cancer patients with non pCR. null France Individuals Patients population Female Young Adult (19 to 24 years) Adult (25 to 44 years) Middle Aged (45 to 64 years) Aged (65 to 79 years) Aged, 80 and over (80 years and more) Inclusion criteria: - A confirmed diagnosis of HER2-positive early breast cancer; - Initiated Herceptin® based neoadjuvant treatment during 2014 (inclusion period) followed by a breast surgery; - A visit to any of the oncologist participating in the study during the 1-year inclusion period. Patients with bilateral breast cancer, or participating in a clinical trial for neoadjuvant or adjuvant treatment, or already included in the registry of another participating site of the study, or who expressed disagreement on the use of their medical data will be excluded from the site’s registry. Clinical data CDISC GCP/GVP Health care consumption and services Other Through organizations (health services or institutions schools businesses etc.) < 500 individuals Converting or copying information into a structured record Observational Study Observational Study Cohort study 301 Unknown Restricted access Access on specific project only